|
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Vinblastine and Methotrexate in Treating Children With Desmoid Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Vinblastine and Methotrexate in Treating Children With Desmoid Tumors Clinical research trials and Vinblastine and Methotrexate in Treating Children With Desmoid Tumors healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Vinblastine and Methotrexate in Treating Children With Desmoid Tumors. Vinblastine and Methotrexate in Treating Children With Desmoid Tumors Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Vinblastine and Methotrexate in Treating Children With Desmoid Tumors clinical trial. Subjects frequently obtain the most expert healthcare possible for their Vinblastine and Methotrexate in Treating Children With Desmoid Tumors condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vinblastine and Methotrexate in Treating Children With Desmoid Tumors  Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
For Condition: desmoid tumor
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Children's Cancer Group,Pediatric Oncology Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with vinblastine and methotrexate in treating children who have desmoid tumors that are recurrent or untreatable with surgery or radiation therapy.
Details: OBJECTIVES: I. Estimate the efficacy and toxicity of vinblastine and methotrexate for newly diagnosed or recurrent desmoid tumors in children who are not good candidates for treatment with surgery or radiation therapy. PROTOCOL OUTLINE: Patients receive vinblastine and methotrexate IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter. PROJECTED ACCRUAL: A total of 13-25 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /21 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven, untreated, primary desmoid tumor (aggressive fibromatosis) for which surgery and/or radiation therapy is not thought to be feasible (prior attempted surgical resection allowed if gross residual disease remains); No other fibroblastic lesions or other fibromatoses allowed - Recurrent desmoid tumor not previously treated with vinca alkaloids or methotrexate and no chemotherapy since recurrence - Measurable disease by MRI --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: Under 19 at time of diagnosis - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Hemoglobin normal for age; WBC normal for age; Platelet count normal for age - Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) for age; SGOT less than 1.5 times ULN for age - Renal: Creatinine less than 1.5 times ULN for age
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SharonMurphy, Study Chair, Pediatric Oncology Group
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Children's Hospital of Orange County
Orange, California, 92668
United States
Princess Margaret Hospital for Children
Perth, Western Australia, 6001
Australia
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York City, New York, 10016
United States
IWK Grace Health Centre
Halifax, Nova Scotia, B3J 3G9
Canada
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700
United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
United States
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84132
United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
United States
Children's Mercy Hospital
Kansas City, Missouri, 64108
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Veterans Affairs Medical Center - Fargo
Fargo, North Dakota, 58102
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128
United States
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
Canada
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105
United States
Children's Hospital of Denver
Denver, Colorado, 80218
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5265
United States
Long Beach Memorial Medical Center
Long Beach, California, 90806
United States
Doernbecher Children's Hospital
Portland, Oregon, 97201-3098
United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
United States
Vanderbilt Cancer Center
Nashville, Tennessee, 37232-6838
United States
Children's Hospital of Columbus
Columbus, Ohio, 43205-2696
United States
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
Children's Hospital Medical Center - Cincinnati
Cincinnati, Ohio, 45229-3039
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198-3330
United States
Additional Information:
Study ID Numbers: CDR0000065601; POG-9650
Study Start Date: April 2000
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003019
Other Desmoid Tumor Studies:
1. Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
2. Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
3. Radiation Therapy in Treating Patients With Aggressive Fibromatoses
Related Studies:
Other desmoid tumor Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
|
|
|
|
|
|
|
|
